The U.S. Food and Drug Administration (FDA) has approved Krystal Biotech Inc's topical gene therapy, Vyjuvek, for the treatment of dystrophic epidermolysis bullosa (DEB), a rare and severe genetic skin disorder. DEB is typically present at birth and causes open wounds, skin infections, and increases the risk of vision loss, scarring, and potentially fatal skin cancer. The approval marks the first-of-its-kind treatment for epidermolysis bullosa. It is estimated that globally, around 9,000-10,000 people are affected by this skin disorder, with about 3,000 individuals in the United States alone experiencing the recessive and dominant forms of the disease.